Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
4D Molecular Therapeutics ( (FDMT) ) has issued an announcement.
On June 27, 2025, Uneek Mehra announced his resignation as Chief Financial and Business Officer of 4D Molecular Therapeutics, effective July 15, 2025, to pursue other opportunities. He will continue to provide advisory services until September 2025, ensuring a smooth transition. The company has started searching for a successor. On July 2, 2025, the company provided updates on its Phase 3 program for wet AMD, noting that enrollment for the 4FRONT-1 trial exceeded expectations, leading to an accelerated timeline for topline data in early 2027. Additionally, the 4FRONT-2 trial began ahead of schedule. The company also announced a 25% workforce reduction in July 2025 to streamline operations, resulting in significant cost savings and extending its cash runway into 2028.
The most recent analyst rating on (FDMT) stock is a Buy with a $45.00 price target. To see the full list of analyst forecasts on 4D Molecular Therapeutics stock, see the FDMT Stock Forecast page.
Spark’s Take on FDMT Stock
According to Spark, TipRanks’ AI Analyst, FDMT is a Neutral.
The overall score is influenced most by the company’s financial performance and technical analysis. Financial challenges are a significant risk, with persistent negative income and cash flow issues. However, technical indicators show some positive momentum. Valuation remains a concern due to negative earnings and no dividend yield.
To see Spark’s full report on FDMT stock, click here.
More about 4D Molecular Therapeutics
4D Molecular Therapeutics is a biotechnology company focused on developing gene therapy products. The company’s primary focus is on treating serious diseases, including wet age-related macular degeneration and cystic fibrosis, through innovative molecular therapies.
Average Trading Volume: 547,251
Technical Sentiment Signal: Sell
Current Market Cap: $192.2M
For a thorough assessment of FDMT stock, go to TipRanks’ Stock Analysis page.